Cargando…

Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry

Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have rapidly become integral to standard-of-care therapy for non-small cell lung cancer and other cancers. Immunohistochemical (IHC) staining of PD-L1 is currently the accepted and approv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inge, L.J., Dennis, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216464/ https://www.ncbi.nlm.nih.gov/pubmed/35757235 http://dx.doi.org/10.1016/j.iotech.2020.04.001

Ejemplares similares

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Multinucleated giant cells of bladder mucosa are modified telocytes: Diagnostic and immunohistochemistry algorithm and relation to PD-L1 expression score
por: Gulinac, Milena, et al.
Publicado: (2023)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Crowdsourcing scoring of immunohistochemistry images: Evaluating Performance of the Crowd and an Automated Computational Method
por: Irshad, Humayun, et al.
Publicado: (2017)

Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
por: Mercier, Anaïs, et al.
Publicado: (2023)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro
por: Sirivisoot, Sirintra, et al.
Publicado: (2023)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
por: Krutzek, Fabian, et al.
Publicado: (2022)

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
por: Roach, Charlotte, et al.
Publicado: (2016)

Accurate expression of PD‐L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry
por: Shinchi, Yusuke, et al.
Publicado: (2019)

Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
por: Maekawa, Naoya, et al.
Publicado: (2023)

Applications of immunohistochemistry
por: Duraiyan, Jeyapradha, et al.
Publicado: (2012)

Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis
por: Xu, Junying, et al.
Publicado: (2021)

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
por: Silva, Manuel A, et al.
Publicado: (2020)

Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review
por: Koomen, Bregje M, et al.
Publicado: (2020)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Comparison of Semi-Quantitative Scoring and Artificial Intelligence Aided Digital Image Analysis of Chromogenic Immunohistochemistry
por: Bencze, János, et al.
Publicado: (2021)

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
por: Udall, Margarita, et al.
Publicado: (2018)

Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction
por: Huang, Dading, et al.
Publicado: (2019)

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
por: Huang, Richard S. P., et al.
Publicado: (2021)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
por: Guo, Hua, et al.
Publicado: (2020)

Optimized PD-L1 scoring of gastric cancer
por: Schoemig-Markiefka, Birgid, et al.
Publicado: (2021)

Automated analysis of images for molecular quantification in immunohistochemistry
por: Guirado, Ramon, et al.
Publicado: (2018)

Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry
por: Haragan, Alexander, et al.
Publicado: (2020)

Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray
por: Martinez-Morilla, Sandra, et al.
Publicado: (2019)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
por: Lee, Yong Seok, et al.
Publicado: (2021)

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
por: Yan, Hongkai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7089nvrqaivlu3jbq4n84tdpbj